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Abstract
Background: Cytomegalovirus (CMV) infection is common among HIV-infected individuals. Its contribution to morbidity 
and mortality became more apparent following introduction of  highly active anti-retroviral therapy (HAART) which improved 
survival among HIV-infected individuals.
Objectives: This study aimed at determining the prevalence of  both active and latent CMV infections among HIV-infected 
individuals on HAART in Ilorin, Nigeria.
Methods: A total of  360 consented HIV-1 patients were recruited for the study. About 5ml of  blood and socio-demographic 
data were collected from each patient. Plasma from the blood was tested for anti-CMV IgM and IgG presence using ELISA.   
Results: Of  the 360 participants tested, 42 (11.7%) and 265 (73.6%) were respectively anti-CMV IgM and IgG antibodies pos-
itive representing active and latent infection rates respectively. Gender and age were the correlates of  IgM seropositivity while 
age, occupation and marital status correlated with IgG seropositivity. Occupation, marital status, use of  HAART and CD4+ 
count were not statistically associated with IgM level while gender, use of  HAART and CD4+ count did not correlate with IgG 
level. 
Conclusions: This study has demonstrated high level of  latent and active CMV infection among HAART recipients in Ilorin 
and highlighted the need for incorporation of  anti-herpes drugs in the treatment regimen.
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Opportunistic infections (OIs) remain a major concern 
in Human Immunodeficiency Virus (HIV) infected in-
dividuals as they contributes significantly to morbidity 
and mortality and are the main reason for hospitaliza-
tion among this cohort1. OIs in HIV-infected individ-
uals can be caused by viruses, bacteria, fungi, protozoa 
and other pathogens. Among the leading cause of  viral 
OIs in HIV-infected individuals are viruses belonging to 
Herpesviridae family including human herpes simplex vi-
rus types 1 and 2 (HSV-1 and HSV-2), Cytomegalovirus 
(CMV), Varicella zoster virus (VZV), and Epstein - Barr 
virus (EBV).
CMV (a member of  the Betaherpesvirinae sub-family) has 
global endemicity and is more widespread in developing 
countries particularly in areas of  low socio-economic 
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conditions2. Its seroprevalence in the general population 
ranges from 50% to 90%3 and increases to 75% to 90% in 
HIV-infected individuals particularly among homosexual 
men4. It is transmitted principally through infected body 
fluids, sexual contact, blood transfusion, during delivery 
and during organ transplant. The virus establishes a life-
long latent infection in infected individuals principally in 
connective tissue cells, such as the endothelium of  blood 
vessels, mononuclear cells, white blood cells, and epitheli-
al cells. The infection is often asymptomatic and acute and 
is followed by lifelong persistence of  the virus in a latent 
stage in immunocompetent subjects but with potentially 
severe consequences in immunocompromised patients5. 
In people with HIV infection, it can present with a wide 
array of  complications such as gastrointestinal tract ulcer-
ation, hepatitis, encephalitis, retinitis, leukopenia and re-
spiratory infections6,7. The prevalence of  these end-organ 
diseases (EODs) was estimated at approximately 40% 
or greater among patients with advanced HIV infection 
prior to the era of  Highly Active Antiretroviral Thera-
py (HAART)8. The advent of  HAART however led to 
improved prognosis among HIV patients with significant 
reduction in EODs.   
Whether CMV acts as a cofactor in accelerating HIV 
pathogenesis or activates opportunistically, without clini-
cal consequence, as a result of  the general impairment in 
cellular immune responsiveness caused by HIV is not yet 
fully understood9,10,11,12,13. Since both viruses are immuno-
suppressive, synergistic effect culminating in accelerated 
disease progression14 cannot be completely ruled out. A 
number of  studies have implicated CMV as a cofactor 
in the pathogenesis of  AIDS15,16,17,18 although its direct 
effect has been difficult to document since most adult 
patients are infected with CMV long before becoming in-
fected with HIV-116,17,19.
A crucial part of  immune system defence against CMV 
is the development of  CMV specific antibodies. The first 
type of  antibody to develop in response to CMV is IgM, 
which develops within a few days following primary in-
fection. While CMV IgM remains detectable for six to 
nine months, medium to high levels of  CMV IgM can 
be detected during the first three months of  a primary 
infection. IgM is also detected during secondary infec-
tions either as re-activation or re-infection. The second 
antibody type to respond to CMV is IgG. This antibody 
develops within 1 to 2 weeks after infection and, once de-
veloped, can be detected throughout life. Consequently, 
IgG is commonly used and widely accepted measure of  
previous/latent CMV infection20 because this virus estab-
lishes a lifelong latent infection in infected individuals.
The aim of  the present study was to evaluate previous/
latent visa vis current/active CMV infection and associ-
ated predictors among a cohort of  HIV-infected individ-




Study design and population
This was a cross-sectional, hospital-based cohort study 
conducted between January and July 2016. The study 
participants included 360 (93 males and 267 females: age 
range 1 - 70 years; mean age 42 years) confirmed HIV-in-
fected individuals attending an anti-retroviral treatment 
center at General hospital Offa, Kwara state. Socio-de-
mographic data were collected using interviewer-admin-
istered questionnaire forms from the study participants.
Sample collection and preparation
Consenting participants were consecutively selected in 
the hospital irrespective of  age, state of  health and gen-
der; exclusion criteria were; no willingness to participate. 
Blood samples were aseptically collected by venipuncture 
from the participants. About 5ml of  blood sample was 
obtained from each participant into a sterile bottle and 
allowed to clot at room temperature before spinning at 
3,000 rpm for 10 minutes. Then serum was aspirated into 
new Eppendorf  tubes, appropriately labelled and stored 
at -20oC until assayed.
Serology
Serum samples were tested for the presence of  IgM and 
IgG antibodies using commercially available Enzyme 
Linked Immunosorbent Assay (ELISA) kit (manufac-
tured by Diagnostic Automation, Inc., Calabasas, CA, 
USA) for detection of  CMV specific IgM and IgG anti-
bodies. The tests were performed and interpreted accord-
ing to the kits’ manufacturer’s instructions.
Ethical clearance
Ethical clearance for the study was obtained from the 
Ethical Review Committee (ERC) of  Kwara state Minis-
try of  Health, Nigeria. Approval was also obtained from 
the hospital involved in this study. There was informed 
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consent from all the participants and parents of  the par-
ticipants in the case of  children before sampling.
Statistical analysis
Data was analysed using Statistical Package for Social Sci-
ences (SPSS version 21). Chi square or Fisher’s exact was 
used where appropriate to test association. A p value of  
<0.05 was considered significant.   
 
Results
Of  the 360 samples tested, 42 (11.7%) tested positive 
foranti-CMV IgM antibody while 265 (73.6%) tested pos-
itive for anti-CMV IgG antibody. Samples were collected 
from 93 (25.8%) males and 267 (74.2%) females (Table 
1). The study shows significant difference (X2=5.32, 
p-value=0.021) in the distribution of  anti-CMV IgM 
antibody between the two gender groups. Higher preva-
lence of  anti-CMV IgM antibody was detected in males 
(18.3%) than females (9.4%). On the other hand, there 
was no significant difference (X2=0.48, p-value=0.488) 
in the distribution of  anti-CMV IgG antibody between 
the two groups. The prevalence of  anti-CMV IgG an-
tibody was also higher in males (76.3%) than in females 
72.7% (Table 1).
Table 1: Relationship between study predictors and detection of anti-CMV IgM/IgG 
antibodies among the HIV-infected study participants 
  
Predictors No tested No (%) 
positive 





Male 93 17 (18.3)   
5.32 (0.021) 
71 (76.3)   
0.48 (0.488) Female 267 25 (9.4) 194 (72.7) 
Age group (years) 












21-30 46 1 (2.2) 33 (71.7) 
31-40 121 15 (12.4) 85 (70.3) 
41-50 89 7 (7.9) 52 (58.4) 
51-60 52 11 (21.2) 46 (88.5) 
˃ 60 38 5 (13.2) 37 (97.4) 
Occupation 












Civil servants 46 1 (4.4) 5 (21.7) 
Artisans 121 0 (0) 14 (82.4) 
Professionals 89 4 (14.3) 18 (64.3) 
Students 52 2 (28.6) 6 (85.7) 
Unemployed 38 7 (16.3) 32 (74.4) 
Marital status 








Married 265 32 (12.1) 195 (73.6) 
Divorced 11 0 (0) 10 (90.9) 
Widowed 7 0 (0) 2 (28.6) 
Total 360 42 (11.7)   265 (73.6)   
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The study also showed significant difference in both an-
ti-CMV IgM antibody (X2=11.251, p-value=0.0466) and 
anti-CMV IgG antibody (X2=29.351, p-value=0.0001) 
among the various age groups tested. It showed that 
highest prevalence (21.4%) of  anti-CMV IgM antibody 
occurred among study participants of  age range ≤ 20 
years. Also, highest prevalence (97.4%) for anti-CMV IgG 
antibody occurred among participants of  age range > 60 
years. Lowest prevalence (2.2%) of  anti-CMV IgM anti-
body was observed among subjects of  age range 21-30 
years while the lowest prevalence (58.4%) for anti-CMV 
IgG antibody was observed among subjects of  age range 
41-50 years (Table 1).
There was no significant difference (X2=6.458, p-val-
ue=0.2642) in the seropositivity outcome of  anti-CMV 
IgM antibody among the various occupational groups. On 
the other hand, significant difference exists in anti-CMV 
IgG antibody among the various occupational groups in 
this study (X2= 37.316, p-value=0.000) (Table 1). High-
est prevalence of  anti-CMV IgM antibody (28.6%) and 
anti-CMV IgG antibody (85.7%) were observed among 
the students. Lowest prevalence (21.7%) of  anti-CMV 
IgG antibody was found among civil servants while an-
ti-CMV IgM antibody was not detected among the arti-
sans in the study group (Table 1).
There was no significant difference (X2= 2.55, p-val-
ue=0.4663) in the seropositivity outcome of  anti-CMV 
IgM antibody among the various marital groups in the 
study. The prevalence was higher among the singles 
(13.0%) than their married counterparts (12.1%) while 
the antibody was not detected among both the divorced 
and widowed participants. The level of  anti-CMV IgG 
antibody seropositivity among the various marital groups 
was statistically significant (X2= 9.12, p-value=0.0277). 
The prevalence was higher among the divorced partici-
pants (90.9%), followed by singles (75.3%), and married 
participants (73.6%) while widowed participants had the 
least prevalence (28.6%) as shown in table 1.
 
Our data also shows that 355 out of  the 360 (98.6%) of  
the study participants were already on HAART while the 
remaining 5 (1.4%) were ART naïve at the time of  sam-
ple collection. Among the former group, 11.8% (42/355) 
and 74.1% (263/355) tested positive for anti-CMV IgM 
and IgG antibodies respectively while 40.0% (2/5) prev-
alence was recorded for anti-CMV IgG antibody among 
the latter group (Figure 1).
 
Figure 1: Relationship between HAART status and detection of anti-CMV IgM/IgG 
antibodies among the HIV-infected study participants 
Key: HAART = Highly active antiretroviral therapy 
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Out of  the 360 study participants, 263 (73.1%) had a 
CD4+ cell count of  ≤350/µL while 97 (26.9%) had a 
CD4+ cell count of  > 350/µL. Among the former group, 
prevalence of  10.7% (28/263) and 71.5% (188/263) for 
anti-CMV IgM and anti-CMV IgG antibodies respective-
ly were recorded while in the later group, prevalence of  
14.4% (14/97) and 79.4% (77/97) for anti-CMV IgM 
and anti-CMV IgG antibodies respectively were recorded 
(Figure 2).            
Discussion
The 11.7% and 73.6% prevalence for CMV IgM and IgG 
antibodies recorded in this study is significant and indi-
cates the level of  on-going and overall burden of  the in-
fection among this cohort of  HIV infected patients in 
Offa Kwara state. This is in consonance with earlier stud-
ies by Fowotade et al.21 and Deborah et al.22 which report-
ed IgM levels of  11.1% among HIV patients in a tertiary 
health facility in Ilorin, Kwara state and 10.5% among 
pregnant women in a secondary health facility in Kafan-
chan, Kaduna states respectively. This indicates signifi-
cant level of  acute/ongoing CMV infection among both 
cohorts of  HIV infected and non-infected individuals in 
our society. Lower CMV IgM levels have earlier been re-
ported among HIV patients in Benin (7.0%)23, pregnant 
women in Benue (3.5%)24 and outside the country among 
pregnant women in Kenya (8.1%)25. On the other hand, 
higher levels of  13.0% and 28.0% of  CMV IgM antibod-
ies have equally been reported by Musa et al.26 and Oladi-
po et al.27 among HIV patients in Kano and among blood 
donors in Ogbomoso, Oyo state respectively. Compared 
to significantly lower rates reported from more developed 
countries28,29,30, the observation of  high active CMV in-
fection in our study and indeed other parts of  Nigeria 
could signify high level of  re-activation or continued on-
going new infections. This is particularly worrisome and 
reinforces the need to address the serious problem which 
high endemicity brings in the study population.
In the event of  re-activation, the fact that majority of  
these patients are already on HAART and none was re-
ported as having any clinical manifestation of  AIDS (data 
not shown) suggests other factors rather than immuno-
suppression as the cause of  the re-activation.
The high prevalence of  73.6% of  CMV IgG antibodies 
recorded in this study is comparable to the 77% IgG anti-
body level reported by Pennap and Ahmed31 among HIV 
patients in Nasarawa state. However, this rate is slightly 
lower compared to prevalence rates reported by other 
researchers from different parts of  Nigeria. Seroprev-
alence of  CMV IgG of  93.3% was reported by Umeh 
 
      Figure 2: Relationship between CD4+ count and detection of anti-CMV IgM/IgG antibodies  
      among the HIV-infected study participants 
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et al.24 among pregnant women in Benue state. Similarly, 
93.9% seroprevalence was reported by Fowotade et al.21 
among HIV patients in Ilorin. Yet higher prevalence rates 
for CMV IgG antibodies have been reported among HIV 
patients by Ojide et al.23 and Kida et al.32 in Benin, Edo 
state and Maiduguri, Borno state respectively. Elsewhere 
outside the country, prevalence of  77.3%25 and 90.0%-
100.0%33,34 were reported from Kenya and India respec-
tively. The high prevalence recorded in Nigeria and other 
developing countries like Kenya and India contrasts with 
lower prevalence rates recorded in more developed coun-
tries in which prevalence ranges from 38.0%-75.0%. Its 
seroprevalence among adult populations in the USA, Aus-
tralia and Europe has been estimated at between 36.0%-
77.0%35. Cultural and economic as well as racial differenc-
es between the developed and developing countries might 
partly explain this observed difference in prevalence rates. 
This view is strongly supported by studies which associ-
ated poor nutrition and low weight36 and crowded living 
conditions37 with increased CMV seroprevalence in Afri-
can studies. Poor nutrition and crowded living conditions 
which are associated with poor economic conditions are 
more likely in developing than developed countries. 
This study also showed significantly higher rate of  acute/
active CMV infection among the male patients than their 
female counterparts as demonstrated by significant-
ly higher IgM in males than females. Previous infection 
(shown by IgG) was also higher in males than females 
although the difference is not statistically significant (p 
> 0.05). Similar studies by Ojide et al.23 and Fowotade et 
al.21 on HIV-infected individuals failed to record any sig-
nificant association between both CMV-specific IgM and 
IgG antibodies and gender of  the patients. The signifi-
cantly higher rate of  acute/active infection among males 
than females in this study suggests more exposure of  
males to factors that lead to re-activation or re-infection 
of  CMV in the study locality and needs to be investigated.
Furthermore, age dependence in the distribution of  both 
anti-CMV IgM and IgG antibodies was demonstrated in 
this study. The higher prevalence of  acute infection re-
corded among patients ≤ 20 years can be attributed to low 
level of  education among this group compared to their 
older counterparts. Furthermore, these patients are teen-
agers and more likely to engage in risky behaviours that 
aids transmission. Similarly, somewhat high prevalence of  
IgM antibody recorded among older patients (51-60 years 
and > 60 years) could be as a result of  re-activation as 
the virus is known to re-activate in old age due to weak-
ened immunity. On the other hand, higher prevalence of  
previous infection (IgG antibodies) among older patients 
(51-60 years and > 60 years) demonstrates the cumulative 
nature of  the infection since the virus maintains latency 
in the body and an infected individual remains infected 
for life. Higher prevalence of  previous/latent infection is 
therefore expected among older population. Similar trend 
was also reported by Fowotade et al.21
Our analysis also showed no association between an-
ti-CMV IgM antibody level and occupation of  the pa-
tients (p > 0.05) while anti-CMV IgG antibody level is 
significantly associated (p < 0.05) with patients’ occupa-
tion. Highest prevalence of  both IgM and IgG antibodies 
among this cohort is reported among the students pop-
ulation. While higher IgM antibody among the students 
can be explained by the earlier view that risky behaviours 
among the students may be higher due to teenage tenden-
cies and low level of  education (majority are in primary 
and secondary schools), no reason for high IgG antibody 
among this group could be advanced at this point since 
higher IgG antibody is expected among other occupa-
tional groups with older patients. Similar studies by Umeh 
et al.24 and Fowotade et al.21 among pregnant women and 
HIV-patients respectively did not find any significant 
association between the distribution of  both anti-CMV 
IgM and IgG antibodies and occupation of  their subjects.
Although not statistically significant (X2=2.55, p=0.4663), 
the prevalence of  anti-CMV IgM antibody is slightly 
higher among single than married patients. The antibody 
was not detected among the widows and divorced pa-
tients. On the other hand, there was statistical association 
(X2=9.12, p=0.0277) in the distribution of  anti-CMV 
IgG antibody among the different marital groups. There 
was an IgG prevalence of  90.9% among the divorced pa-
tients. This is followed by singles (75.3%) and married 
patients (73.6%) respectively while the least prevalence 
(28.6%) was recorded among the widows. Similar study 
by Fowotade et al.21 reported significant association in the 
distribution of  both IgM and IgG antibodies among dif-
ferent marital groups.
Majority, 98.6% (355/360) of  the participants in this study 
were on HAART while the remaining, 1.4% (5/360) were 
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antiretroviral treatment (ART) naïve at the time of  study. 
Among those on HAART, 11.8% (42/355) tested posi-
tive to anti-CMV IgM antibody while 74.1% (263/355) 
also tested positive to anti-CMV IgG antibody. Forty per-
cent (40.0%) prevalence of  anti-CMV IgG antibody was 
recorded among the ART naïve patients while IgM anti-
body was not detected among them (Figure 1). Further-
more, none of  the patients was reported of  having any 
clinical manifestation of  AIDS and none was receiving 
any anti-herpes drugs (AHDs) (data not shown) at the 
time of  the study. Although the sample size is skewed in 
favour of  HAART experienced compared to naïve pa-
tients, detection of  anti-CMV IgM antibody among the 
former group and not among the latter indicates that 
re-activation/or new infection of  CMV occurs indepen-
dent of  HAART-mediated HIV suppression. Similar 
result was also recorded for IgG antibody level. Higher 
prevalence (74.1%) of  IgG antibody was recorded among 
HAART experienced than naïve patients with prevalence 
of  40.0%. This therefore underscores the need to incor-
porate AHDs in the treatment regimen for HIV-infect-
ed patients in this locality considering the reported high 
prevalence. This is in consonance with previous report 
by Pennap and Ahmed31 in which higher prevalence of  
anti-CMV IgG antibody was reported among drug expe-
rienced than naïve patients. It is however a clear depar-
ture from a trend reported by Fowotade et al.21 in which 
higher prevalence of  both IgM and IgG antibodies were 
reported among drug naïve than experienced patients.   
      
Since CD4+ cell count is an acceptable measure of  im-
mune status among HIV-infected individuals, we also an-
alysed the result based on the CD4+ cell count of  the 
patients. Presently in Nigeria, antiretroviral therapy for 
HIV-infected individuals commences when the CD4+ 
cell count declines to below 350 /µL. Hence, we grouped 
the patients into two based on their CD4+ cell count; 
those with CD4+ cell count of  ≤350 /µL and those with 
CD4+ cell count of  > 350 /µL. Our analysis surprisingly 
showed higher prevalence of  both anti-CMV IgM and 
IgG antibodies among patients with higher CD4+ cell 
counts (≤ 350 /µL) compared to their counterparts with 
lower CD4+ cell counts (≤350 /µL) although the differ-
ence is not statistically significant (p > 0.05) (Figure 2). 
Similar studies in Benin, Nigeria23 and Iran38 also found 
no significant association between the CD4+ cell level and 
seroprevalence of  CMV. The reason for this observation 
is not immediately known to this study. However, since 
majority of  the study participants are on HAART which 
affects CD4+ cell counts, type of  therapy and duration 
may be likely factors.
Conclusion
The prevalence of  both latent and active CMV infection 
is high among HIV-1 infected individuals in Offa, Kwara 
state Nigeria and occurs irrespective of  HAART status. 
This suggests that the patients still engage in risky be-
haviours that aids transmission of  the virus. In addition 
to mass education aimed at sensitizing the general public, 
there is also the need to incorporate anti-herpes medica-
tions in the treatment regimen of  the HIV-1 patients to 
reduce CMV associated morbidity and mortality.   
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